Progressive Multiple Sclerosis: Latest Research, Emerging Therapies, and Clinical Trials
The Progressive MS Challenge
Primary progressive MS (PPMS) and non-active secondary progressive MS (SPMS) remain difficult to treat. In these forms, neurodegeneration dominates while inflammation becomes compartmentalized behind the blood-brain barrier, limiting the reach of conventional immunomodulatory therapies.
Active Research Avenues
1. Neuroprotection & Remyelination
- Clemastine (antihistamine): The ReBUILD trial demonstrated modest remyelination measured by visual evoked potential latency improvement.
- Opicinumab (anti-LINGO-1): Phase 2 results were mixed; further development paused.
- Elezanumab (anti-RGMa): Promotes axonal growth and remyelination; Phase 2 ongoing.
- Metformin + clemastine: Repurposing trial (CCMR One) exploring synergistic remyelination.
- High-dose biotin: Failed Phase 3 (SPI2); not recommended.
2. Innate Immunity & Microglial Modulation
- BTK inhibitors: Evobrutinib, tolebrutinib, fenebrutinib cross the blood-brain barrier to target microglia and B cells. Phase 3 trials in RMS and PPMS (HERCULES, PERSEUS, GEMINI).
- S1P modulators: Siponimod (approved for SPMS/PPMS), ozanimod, ponesimod—sequester lymphocytes and may have direct CNS effects.
- TREM2 agonists: Enhance microglial homeostatic function (preclinical).
3. Stem Cell & Cellular Therapies
- AHSCT (autologous hematopoietic stem cell transplant): Resets the immune system; best for active inflammatory progressive MS. MIST trial: 78% NEDA at 5 years.
- Mesenchymal stem cells (MSCs): Neurotrophic and immunomodulatory; Phase 2 trials (MESEMS, ACTIMUS) show mixed results.
- Neural stem cells: Early phase; remyelination potential.
4. Genetic & Molecular Targets
- ASO therapy: Targeting C9orf72 (ALS/FTD overlap), SLC1A2 (excitotoxicity).
- Mitochondrial enhancers: Leriglitazone (PPARγ agonist), nicotinamide riboside.
- Iron chelation: Deferiprone reduces chronic active lesions and smoldering inflammation.
5. Symptomatic & Rehab Innovations
- Digital therapeutics: gait analysis, cognitive training apps.
- Robotics/exoskeletons for gait training.
- Non-invasive brain stimulation (tDCS, rTMS) for fatigue, cognition, spasticity.
- Biomarker-guided treatment: neurofilament light (NfL), GFAP, smoldering lesions on MRI.
6. Combination Strategies
Anti-inflammatory (DMT) + neuroprotective + rehabilitation = rational polytherapy. Trials: OCTOPUS (adaptive platform), ChariotMS (cladribine + advanced SPMS).
Clinical Trial Participation
- Essential for progress. Ask your neurologist or search ClinicalTrials.gov (condition: "Multiple Sclerosis, Progressive").
- Expanded access programs for promising agents.
Current Standard of Care
- PPMS: Ocrelizumab (only FDA-approved).
- Active SPMS: Siponimod, ozanimod, ponesimod, cladribine, ocrelizumab, ofatumumab.
- Non-active progressive: Symptom management, rehabilitation, comorbidity control, clinical trials.
Hope is grounded in science. The pipeline is richer than ever.
Multiple Sclerosis - Related Articles
- Multiple Sclerosis Relapse: Symptoms, Identification & Management
- Magnet Therapy for Multiple Sclerosis: Exploring Potential Benefits
- Subchondral Sclerosis: Imaging, Pathophysiology, and Link to Osteoarthritis
- Scleroderma: Causes, Risk Factors, and Pathophysiology
- Communicating with Your Doctor About Multiple Sclerosis: A Comprehensive Guide
- Sclerotic Changes: Causes, Organ-Specific Conditions & Treatment
- 12 MS Triggers and How to Avoid Them
